VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel

PHASE4CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Diabetes Mellitus Type IIAcute Coronary Syndrome
Interventions
DRUG

Prasugrel.

Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician´s criteria.

DRUG

Clopidogrel

Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.

Trial Locations (1)

41013

Hospital Universitario Virgen del Rocío, Seville

All Listed Sponsors
collaborator

Andaluz Health Service

OTHER_GOV

lead

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

OTHER

NCT01684813 - VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel | Biotech Hunter | Biotech Hunter